Home News & Events Events Events Page tools Share Share Share on FacebookShare on XShare on LinkedinShare on Bluesky Print Search Email Accessibility Filter events Filter events by clicking within the ‘Category’ drop-down list. Category - Any -IndustryWebinarsWorkshop Workshop Beginners/Intermediate Online NONMEM/PDx-Pop Workshop Date 19 May 2026 - 20 May 2026 Time 08:00 - 18:00 Location Online/Webex Timezone America/New York Workshop Advanced Online NONMEM/PDx-Pop Workshop Date 21 May 2026 Time 09:00 - 17:00 Location Online/Webex Timezone America/New York Industry ASCO Date 29 May 2026 - 2 June 2026 Time 08:00 - 18:00 Location Chicago, IL, USA Timezone America/Chicago ICON will exhibit | Booth #35093 Workshop New and Advanced Features of NONMEM 7.6 Workshop Date 1 June 2026 Time 09:00 - 17:00 Location Dubrovnik, Croatia Timezone Europe/Bratislava Previous 1 2 3 In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events Webinars Workshops Webinars Social media Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media Related information: Solutions Webinars Solutions Industry events Solutions Workshops What's happening in ICON ICON Plc Join ICON at #OCT Southeast on 10 March at 9:30am EST as Shelley McLendon, Senior Vice President, Program Management, shares a CRO perspective on the global biotech sector. She will discuss the landscape shaping biotec... 5 Mar View post View webpage ICON Plc Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging... 5 Mar View post View webpage ICON Plc On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP‑1‑Based Therapeutics Summit for his session, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He will offer a fo... 4 Mar View post View webpage ICON Plc Neuroscience programmes demand reliable feasibility, broad patient access, and operational consistency across regions. At ADPD 2026, stop by booth \#29 to learn how ICON combines informatics driven feasibility, extensi... 4 Mar View post View webpage ICON Plc On 17-21 March at #ADPD2026, visit us at booth #29 to speak with our experts to learn how ICON is working to improve drug development and advance treatments for Alzheimer’s and Parkinson's disease and other movement diso... 4 Mar 4 View post View webpage ICON Plc Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a... 3 Mar View post View webpage ICON Plc Ahead of World Obesity Day tomorrow, explore how ICON successfully supported a sponsors cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate ... 3 Mar View post View webpage ICON Plc Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h... 3 Mar View post View webpage ICON Plc Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe... 2 Mar View post View webpage ICON Plc Sponsors with multi-indication assets can benefit from taking a precision approach to patient screening that enables stratification by relevant comorbidities and related factors. Learn more trial design considerations ... 2 Mar View post View webpage ICON Plc At #OCT Southeast on 10–11 March, ICON will showcase the operational, scientific and digital expertise that helps biotechs navigate complexity and deliver studies with greater certainty. Visit Booth \#37 to speak with ... 2 Mar View post View webpage
